Qiagen and Bristol-Myers Squibb have entered an agreement to look into the use of next-generation sequencing in the development of gene expression profiles as prognostic or predictive tools for immuno-oncology therapies developed by BMS. Qiagen, under a separate agreement, has also obtained from Johns Hopkins University a global license for genetic biomarkers for microsatellite instability and mismatch repair, as well as an option to commercialize next-generation sequencing assays for MSI and MMR status assessment.
Qiagen reaches 2 NGS assay agreements
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.